HEIDELBERG – 03 July 2019 – DOASENSE GmbH, an in vitro diagnostics company focused on the development and commercialization of innovative rapid tests, today announced the commercial launch of the first suite of products for point-of-care testing for direct oral anticoagulants (DOAC). The CE marked range of products was recently completed by the DOASENSE Reader, which enables automated analysis of the company’s DOAC Dipstick test. DOASENSE will present the full DOAC test product suite at the upcoming congress of the International Society on Thrombosis and Haemostasis (ISTH) in Melbourne.

As the use of DOACs is steadily growing, the need for specific anticoagulant checks is likewise increasing. These checks, however, are very time-consuming and often unavailable. DOASENSE offers a fast test that produces reliable results for both factor Xa and thrombin inhibitors within 10 minutes with one single DOAC Dipstick urine test. DOASENSE’s point-of-care test (POCT) is receiving broad interest, e.g. from the field of critical care, where every minute counts, as it answers the question whether a patient has ingested a DOAC. Thus, the necessary therapeutic decision can be taken as quickly as possible.

“We are extremely proud to be bringing now our full suite of DOAC test products to market,” said Prof. Dr. med. Job Harenberg, Founder and Managing Director. “With the additional successful completion of our multi-center clinical follow-up, involving more than 900 patients, we are confident to provide further evidence on the accuracy and advantages of our DOAC Dipstick test soon.”

About the DOASENSE Product Suite:
The CE-marked DOAC Dipstick is a qualitative all-in-one POCT for both direct factor Xa and thrombin inhibitor DOACs. The test is performed using a urine sample from the patient. The DOAC Dipstick provides results within 10 minutes where they are needed most: at the point-of-care. Specially developed accessories complete the first suite of CE-marked products for rapid point-of-care DOAC testing: Objective documentation of results can be achieved with the compact, automated DOASENSE Reader. And the DOASENSE Control Urines are specially designed reference substances to support quality assurance needs. The in vitro diagnostic products are for professional use only.

DOASENSE is a medical technology company with operations in Heidelberg, Germany. DOASENSE’s exclusive, patent protected technology changes the way of testing for direct oral anticoagulants, serving an unmet clinical need. The company is open to distributor inquiries for further broadening the international market presence of its products.

References: Harenberg J et al., Semin Thromb Hemost 2019; 45: 275–284

DOASENSE GmbH, Waldhofer Str. 102, 69123 Heidelberg, Germany
info@doasense.de                    www.doasense.de

Share this story, choose your platform!